FDA approves Skyrizi for pediatric use in psoriatic disease

The FDA approved risankizumab-rzaa for children aged at least 6 years with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy or active psoriatic arthritis, AbbVie announced in a press release. In addition, the FDA approved a new 55 mg prefilled syringe to support weight-based dosing for patients who weigh less than 40 kg. A 150 mg prefilled syringe and